Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07823712
Recruiting Observational

GNRI and PNI for Predicting Short-Term Outcomes in Older Adults With Multiple Rib Fractures

NCT07823712 · tracked via the Priya Life Science Turkey tracker
Sponsor
Ankara Etlik City Hospital
Phase
Observational
Started
2026-09-16
Last updated
2026-09-17

Condition(s) studied

Multiple Rib FracturesIsolated Blunt Thoracic Trauma

Study summary

This prospective observational cohort study will evaluate whether the Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI) can predict short-term clinical outcomes in adults aged 65 years or older with isolated blunt thoracic trauma and more than three rib fractures. Participants will be enrolled in the Emergency Department of Ankara Etlik City Hospital. No experimental drug, device, or additional invasive procedure will be used. Routine clinical, laboratory, anthropometric, imaging, and follow-up data will be recorded. The study plans to include 294 participants. The primary outcome is a composite short-term poor clinical outcome, including in-hospital mortality, intensive care unit admission, invasive or non-invasive mechanical ventilation, pneumonia, atelectasis, tube thoracostomy, or hospital stay of 7 days or longer. The prognostic performances of GNRI and PNI will be compared. Secondary outcomes include the individual components of the composite outcome, new pneumothorax or hemothorax, hospital and intensive care unit length of stay, 30-day emergency department revisit, and 30-day mortality.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age 65 years or older. 2. Presentation to the emergency department with blunt thoracic trauma. 3. More than three rib fractures confirmed by thoracic computed tomography or another appropriate radiologic method. 4. Isolated thoracic trauma without major extra-thoracic injury. 5. Serum albumin level, total lymphocyte count, height, and weight available within the first 24 hours after presentation. 6. Written informed consent obtained from the patient or the legally authorized representative. Exclusion Criteria: 1. Penetrating thoracic trauma. 2. Single rib fracture. 3. Intubation at presentation. 4. Polytrauma or major extra-thoracic injury. 5. Known advanced liver failure, nephrotic syndrome, end-stage renal disease, or hematologic disease that may substantially affect albumin or lymphocyte levels. 6. Active malignancy or cachexia related to advanced malignancy. 7. Missing data. 8. Refusal to participate in the study.

Primary outcome measure(s)

  • Composite In-Hospital Adverse Outcome in Older Adults With Multiple Rib Fractures — From enrollment through discharge from the index hospitalization, or up to 30 days after enrollment, whichever occurs first.
    Occurrence within the index hospitalization or up to 30 days after enrollment of any of the following: in-hospital mortality; intensive care unit admission; invasive or non-invasive mechanical ventilation; pneumonia; atelectasis; chest tube placement due to pneumothorax or hemothorax; or total hospital length of stay of 7 days or longer.

Trial sites (1)

FacilityCityRegionStatus
Ankara Etlik City Hospital, Department of Emergency Medicine Ankara Ankara Recruiting

More Ankara Etlik City Hospital trials in Turkey

Menstrual Status, Anesthetic Consumption, and PONV Recruiting
Effectiveness of TMS on Spasticity and Balance for Patients With MS Recruiting
Perfusion Index for Predicting Diabetic Ketoacidosis Severity in the Emergency Department Recruiting
MAP- Versus Cardiac Index-Guided Hemodynamic Management in Whipple Surgery Recruiting
Comparison of Conventional and Retroclavicular Approaches for Ultrasound-guided Infraclavicular Brachial Plexus Block Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07823712 on ClinicalTrials.gov ↗ ← All trials in Turkey